Page 1

Report: Therapeutic Class Report Overview Hepatitis C Virus Infection Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview Hepatitis C Virus Infection Report Details

• • • • • • •

Publish date: 4th Feb, 2013 Number of slides: 31 Geographic coverage: Global Available format: PDF, CD, Hardcopy Price for Single User License: USD 1,000 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview Hepatitis C Virus Infection Report Insights

• The launch of Protease Inhibitors (PIs) created a wave in 2011-2012 • It accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations • Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future • Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by:  GILD buying VRUS for USD 11 bn  Bristol-Myers Squibb (BMY) acquired Inhibitex for USD 2.5 bn  VRTX acquired Virochem in 2009 for USD 375 mn  In-licensed Alios VX-135 in 2012 for total of USD 775 mn  Abbott in-licensed Enantas ABT-450 for total of USD 310 mn www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview Hepatitis C Virus Infection Report Insights (Continued)

• In the next spurt of M&A in this sector, companies which offer differentiated MOA are expected to be in the limelight, comprising:  Alleviate the need for Ribavarin  Address resistance, non-responders, Liver cirrhosis, HIV-HCV -co infection etc  Target other genotypes  Vaccines or Boosters of immune system

• Analysis of novel pipeline candidates, which target unmet needs, offer promise of an all oral IFN-free treatment with at par or better efficacy and novel vaccine candidates

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview Hepatitis C Virus Infection Table of Contents

• • • • • • •

Executive Summary Progress in the Clinical Development of HCV drugs Competitive Landscape - IFN-Free drugs Market Dynamics- Present and Future HCV Vaccines HCV-HIV Co-infection Annexure

www.researchonglobalmarkets.com


Interested in this report? To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com

Therapeutic class report overview hepatitis c virus infection  
Read more
Read more
Similar to
Popular now
Just for you